Table 3.
Participants becoming eligible by PLCOm2012 alone, by LLPv2 alone and by reaching eligibility by either score, stratified by age at baseline
| Age at baseline | ||||
| 55–59 years | 60–64 years | 65–69 years | 70–74 years | |
| LHC attendees, N | 2835 | 2677 | 2597 | 2190 |
| PLCOm2012 | ||||
| LHC attendees ineligible at baseline, n | 1839 | 1401 | 1169 | 936 |
| LHC attendees becoming eligible | 684 (37%) | 374 (27%) | 188 (16%) | 49 (5.2%) |
| Years to eligibility, median (IQR) | 7 (3–12) | 6 (3–9) | 4 (2–5) | 2 (1–3) |
| LLPv2 | ||||
| LHC attendees ineligible at baseline, n | 2312 | 1444 | 1119 | 740 |
| LHC attendees becoming eligible | 930 (40%) | 281 (19%) | 53 (4.7%) | 1 (0.1%) |
| Years to eligibility, median (IQR) | 8 (4–10) | 5 (4–7) | 4 (3–5) | 4 (4–4) |
| Either PLCOm2012 or LLPv2 | ||||
| LHC attendees ineligible at baseline, n | 1750 | 1175 | 917 | 617 |
| LHC attendees becoming eligible | 722 (41%) | 336 (29%) | 129 (14%) | 23 (3.7%) |
| Years to eligibility, median (IQR) | 7 (3–11) | 5 (3–9) | 4 (2–5) | 2 (1–3) |
LHC, Lung Health Check; LLPv2, Liverpool Lung Project version 2; PLCOm2012, Prostate, Lung, Colorectal and Ovarian trial’s risk model 2012.